Home › Compound Library › Oxiracetam

Oxiracetam

Racetamoral · inferred

Water-soluble racetam with stimulant-like properties. Well absorbed (56-82% bioavailability), primarily cleared renally (~84% unchanged in urine). Enhances cholinergic and glutamatergic neurotransmission. More stimulating than piracetam with particular benefit for logical/analytical thinking.

Projected serum levels — 800 mg, twice daily

Oxiracetam
Oxiracetam modeled serum levels, 800 mg twice daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 125 250 375 500 Day 0 Day 4 Day 7 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 800 mg twice daily (oral).

Modeled steady state after ~1 days: peak ≈ 406 mg, trough ≈ 54.9 mg body load. Population-based estimate over 15 days for a 800 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Racetam
Route modeled
Oral
Model confidence
inferred
Half-life
5 h
Common dose
800 mg
Suggested maximum
2.4k mg/day
Reference dose range
400–2.4k mg (single dose)
Suggested cadence
twice daily
Validated against
800 mg oral — Cmax 19 mg/L at 1 h

Research behind this entry

  1. Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial Gao Y et al. · European Journal of Neurology, 2023 DOI

    Phase IV RCT in vascular cognitive impairment patients showed oxiracetam (800 mg TID) improved cognitive function as measured by MMSE and MoCA scores compared to placebo.

  2. Oxiracetam pharmacokinetics following single and multiple dose administration in the elderly Perucca E et al. · European Journal of Drug Metabolism and Pharmacokinetics, 1987 DOI

    Characterised oxiracetam pharmacokinetics in elderly subjects: 56-82% bioavailability, 3-6h half-life, clearance 9-95 mL/min, and predominantly renal excretion with 84% recovered unchanged in urine.

  3. Clinical studies with oxiracetam in patients with dementia of Alzheimer type and multi-infarct dementia of mild to moderate degree Maina G et al. · Neuropsychobiology, 1989 DOI

    Double-blind placebo-controlled study in dementia patients demonstrated statistically significant improvement in attention, concentration, and memory tasks with oxiracetam 800 mg BID.

  4. Efficacy and safety of oxiracetam in patients with vascular cognitive impairment: A multicenter, randomized, double-blinded, placebo-controlled, phase IV clinical trial. Lim JS, Lee J, Kang Y, Park HT, Kim DE, Cha JK, Park TH, Heo JH, Lee KB, Park JM, Oh MS, Kim EG, Chang DI, Heo SH, Park MS, Park H, Yi S, Lee YB, Park KY, Lee SJ, Kim JG, Lee J, Cho KH, Rha JH, Kim YI, Lee JH, Choi JC, Oh KM, Kwon JH, Kim C, Park JH, Jung KH, Sung SM, Chung JW, Lee YS, Kim HY, Cho HJ, Park JW, Moon WJ, Bae HJ · Contemporary clinical trials, 2023 DOI

    This citation reports a human clinical study involving Oxiracetam. It does not by itself establish a qualified dose, safety profile, efficacy claim, or pharmacokinetic route for this record.

4 published studies referenced in the app, each with a plain-language summary.